Aberrant activation of the PI3K/AKT/mTOR axis is associated with poor clinical outcome in ALL, and its dysregulation can induce cell survival and resistance to cytotoxic drugs (Batista et al., 2011; Gomes et al., 2014; Khanna et al., 2018). This evidence concerns the gene MTOR and acute lymphoblastic leukemia.